Market Research Industry Reports

X4 Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

X4 Pharmaceuticals Inc (X4 Pharma) is a clinical stage biotechnology company that develops novel therapeutics to treat cancer and rare diseases. The companys lead drug candidate, X4P-001-LD, is in Phase 2/3 trial used for the treatment for patients with WHIM and other immunodeficiencies. It also develops X4P-001, a CXCR4 inhibitor used for the treatment of melanoma, refractory clear cell renal cell carcinoma (ccRCC), and other solid tumor indications. X4 Pharmas pre-clinical products include X4P-002, designed for the treatment of brain cancers, including glioblastoma multiforme. X4 Pharma is headquartered in Cambridge, Massachusetts, the US.

X4 Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
X4 Pharma Raises USD25.8 Million in Venture Financing 10
X4 Pharma Raises USD37.5 Million in Series A Financing Round 11
X4 Pharma Raises USD0.7 Million in Seed Financing Round 12
Partnerships 13
X4 Pharma Enters into Research Agreement with Yale University 13
Equity Offering 14
X4 Pharma Spin Off from Sanofi 14
X4 Pharmaceuticals Inc - Key Competitors 15
X4 Pharmaceuticals Inc - Key Employees 16
X4 Pharmaceuticals Inc - Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Jan 23, 2017: X4 Pharmaceuticals Appoints Dr. Sudha Parasuraman as Chief Medical Officer 18
Product News 19
05/25/2017: X4 Pharmaceuticals Announces Initiation of the Phase 2 Expansion of its Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 19
01/30/2017: X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease 20
01/26/2017: X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List Of Tables

List of Tables
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
X4 Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
X4 Pharma Raises USD25.8 Million in Venture Financing 10
X4 Pharma Raises USD37.5 Million in Series A Financing Round 11
X4 Pharma Raises USD0.7 Million in Seed Financing Round 12
X4 Pharma Enters into Research Agreement with Yale University 13
X4 Pharma Spin Off from Sanofi 14
X4 Pharmaceuticals Inc, Key Competitors 15
X4 Pharmaceuticals Inc, Key Employees 16

List Of Figures

List of Figures
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2018

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2018Tumor Necrosis Factor

USD 3500View Report

X4 Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

X4 Pharmaceuticals Inc (X4 Pharma) is a clinical stage biotechnology company that develops novel therapeutics to treat cancer and rare diseases. The companys lead drug candidate, X4P-001-LD, is in Phase

USD 250View Report

Oric Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Oric Pharmaceuticals Inc (Oric Pharmaceuticals) is an independent cancer therapy company that focuses on the discovery and development of drugs for overcoming resistance in cancer. Its lead drug candidate ORIC-101,

USD 250View Report

Alexza Pharmaceuticals Inc - Strategic SWOT Analysis Review

Alexza Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information

USD 125View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Mar 2018
No. of Pages :22
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube